Antiobesity effect of Pediococcus pentosaceus LP28 on overweight subjects: A randomized, double-blind, placebo-controlled clinical trial

European Journal of Clinical Nutrition

Volumn 70, Issue 5, 2016, Pages 582-587

  Higashikawa, F ^a   Noda, M ^a   Awaya, T ^b   Danshiitsoodol, N ^a   Matoba, Y ^a   Kumagai, T ^a   Sugiyama, M ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ANTIOBESITY AGENT; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROBIOTIC AGENT; RESISTIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BACTERIAL STRAIN; BODY FAT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FAT MASS; FEMALE; FISHER EXACT TEST; FLATULENCE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HEAT; HOMEOSTASIS; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MALE; NAUSEA; NONHUMAN; NORMAL HUMAN; OBESITY; PEDIOCOCCUS PENTOSACEUS; PEDIOCOCCUS PENTOSACEUS LP28; POWDER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; SUBCUTANEOUS TISSUE DISORDER; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WAIST CIRCUMFERENCE; ADIPOSE TISSUE; MICROBIOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADIPOSE TISSUE; ADULT; AGED; ANTI-OBESITY AGENTS; BODY MASS INDEX; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OVERWEIGHT; PEDIOCOCCUS PENTOSACEUS; PROBIOTICS; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 84960157359     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2016.17     Document Type: Article

References (26)

1. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ et al. for the Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (body mass index) National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011; 377: 557-567.
2. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 2005; 67: 152-162.
3. Lindström J, Peltonen M, Eriksson JG, Ilanne-Parikka P, Aunola S, Keinänen-Kiu-kaanniemi S et al. Finnish Diabetes Prevention Study (DPS). Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia 2013; 56: 284-293.
4. Medina-Gomez G, Vidal-Puig A. Gateway to metabolic syndrome. Nat Med 2005; 11: 602-603.
5. Zhao X, Higashikawa F, Noda M, Kawamura Y, Matoba Y, Kumagai T et al. The obesity and fatty liver are reduced by plant-derived Pediococcus pentosaceus LP28 in high fat diet-induced obese mice. PLOS One 2012; 7: e30696.
6. Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. J Nutr 2000; 130: 396S-402S.
7. Adolfsson O, Meydani SN, Russell RM. Yoghurt and gut function. Am J Clin Nutr 2004; 80: 245-256.
8. Kumar M, Nagpal R, Kumar R, Hemalatha R, Verma V, Kumar A et al. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res 2012; 2012: 902917.
9. de Moreno de LeBlanc A, Matar C, Perdigón G. The application of probiotics in cancer. Br J Nutr 2007; 98: S105-S110.
10. Lee HY, Park JH, Seok SH, Baek MW, Kim DJ, Lee KE et al. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. Biochim Biophys Acta 2006; 1761: 736-744.
11. Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 2008; 49: 821-830.
12. Wada T, Noda M, Kashiwabara F, Jeon HJ, Shirakawa A, Yabu H et al. Characterization of four plasmids harboured in a Lactobacillus brevis strain encoding a novel bacteriocin, brevicin 925 A, and construction of a shuttle vector for lactic acid bacteria and Escherichia coli. Microbiology 2009; 155: 1726-1737.
13. Jin H, Higashikawa F, Noda M, Zhao X, Matoba Y, Kumagai T et al. Establishment of an in vitro Peyer's patch cell culture system correlative to in vivo study using intestine and screening of lactic acid bacteria enhancing intestinal immunity. Biol Pharm Bull 2010; 33: 289-293.
14. Higashikawa F, Noda M, Awaya T, Nomura K, Oku H, Sugiyama M. Improvement of constipation and liver function by plant-derived lactic acid bacteria: a double-blind, randomized trial. Nutrition 2010; 26: 367-374.
15. Nomura M, Kobayashi M, Narita T, Kimoto-Nira H, Okamoto T. Phenotypic and molecular characterization of Lactococcus lactis from milk and plants. J Appl Microbiol 2006; 101: 396-405.
16. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212-228.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
18. IBM SPSS Statistics. Available from: http://www-01.ibm.com/software/analytics/spss/products/statistics/(accessed on 27 February 2016).
19. Li P, Stuart EA, Allison DB. Multiple imputation: a flexible tool for handling missing data. JAMA 2015; 314: 1966-1967.
20. Wang YC, McPherson K, Marsh T, Gortmarker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011; 378: 818-825.
21. Lee JW, Brancati FL, Yeh HC. Trends in the prevalence of type 2 diabetes in Asians versus whites: results from the United States National Health Interview Survey, 1997-2008. Diabetes Care 2011; 34: 353-357.
22. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P et al. Obesity and the risk of myocardial infarction in 27, 000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640-1649.
23. Savva SC, Lamnisos D, Kafatos AG. Predicting cardiometabolic risk: waist-to-height ratio or BMI. A meta-analysis. Diabetes Metab Syndr Obes 2013; 6: 403-419.
24. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-661.
25. Cao H. Adipocytokines in obesity and metabolic disease. J Endocrinol 2014; 220: T47-T59.
26. Lee S, Kwak HB. Role of adiponectin in metabolic and cardiovascular disease. J Exerc Rehabil 2014; 10: 54-59.